Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SDYOQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
NV106
|
|||||
| Synonyms |
Antibody-conjugated panobinostat liposomal nanoparticle; NV 106; NV-106; B7H3/panobinostat nanoparticles
Click to Show/Hide
|
|||||
| Organization |
NanoValent Pharmaceuticals, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Glioblastoma [ICD11:2A00]
Clinical candidate
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Panobinostat
|
Payload Info | ||||
| Therapeutic Target |
Histone deacetylase 1 (HDAC1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.